$116 Million is the total value of Boxer Capital, LLC's 15 reported holdings in Q4 2015. The portfolio turnover from Q3 2015 to Q4 2015 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MRTX | New | MIRATI THERAPEUTICS INC | $63,934,000 | – | 2,023,232 | +100.0% | 55.20% | – |
| AQXP | New | AQUINOX PHARMACEUTICALS INC | $10,101,000 | – | 809,415 | +100.0% | 8.72% | – |
| BPMC | New | BLUEPRINT MEDICINES CORP | $8,261,000 | – | 313,626 | +100.0% | 7.13% | – |
| SGEN | New | SEATTLE GENETICS INC | $7,181,000 | – | 160,000 | +100.0% | 6.20% | – |
| KURA | New | KURA ONCOLOGY INC | $5,499,000 | – | 654,595 | +100.0% | 4.75% | – |
| VTAE | New | VITAE PHARMACEUTICALS INC | $4,530,000 | – | 250,270 | +100.0% | 3.91% | – |
| ARDMQ | New | ARADIGM CORP | $4,373,000 | – | 1,101,513 | +100.0% | 3.78% | – |
| ZGNX | New | ZOGENIX INC | $3,317,000 | – | 225,000 | +100.0% | 2.86% | – |
| CLDN | New | CELLADON CORP | $2,058,000 | – | 1,399,991 | +100.0% | 1.78% | – |
| AKTX | New | AKARI THERAPEUTICS PLCsponsored adr | $2,029,000 | – | 139,899 | +100.0% | 1.75% | – |
| SPHS | New | SOPHIRIS BIO INC | $1,780,000 | – | 1,000,000 | +100.0% | 1.54% | – |
| NBRV | New | NABRIVA THERAPEUTICS AGsponsored adr | $1,688,000 | – | 176,710 | +100.0% | 1.46% | – |
| NVET | New | NEXVET BIOPHARMA PUB LTD CO | $528,000 | – | 154,840 | +100.0% | 0.46% | – |
| ALDX | New | ALDEYRA THERAPEUTICS INC | $428,000 | – | 63,146 | +100.0% | 0.37% | – |
| New | ESSA PHARMA INC | $119,000 | – | 28,100 | +100.0% | 0.10% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Aviva Holdings Ltd. #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-02-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MIRATI THERAPEUTICS INC | 32 | Q3 2023 | 55.2% |
| BEIGENE LTD | 31 | Q3 2023 | 15.6% |
| KURA ONCOLOGY INC. | 24 | Q3 2021 | 4.7% |
| ROCKET PHARMACEUTICALS INC | 23 | Q3 2023 | 5.4% |
| DBV TECHNOLOGIES S A | 23 | Q3 2023 | 3.9% |
| MEI PHARMA INC | 21 | Q2 2023 | 1.4% |
| SYNDAX PHARMACEUTICALS INC | 20 | Q3 2021 | 3.1% |
| GOSSAMER BIO INC | 19 | Q3 2023 | 4.7% |
| ODONATE THERAPEUTICS INC | 18 | Q1 2022 | 12.5% |
| ESPERION THERAPEUTICS INC NE | 18 | Q2 2021 | 11.0% |
View Boxer Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| IDEAYA Biosciences, Inc. | February 14, 2023 | 2,202,812 | 4.6% |
| Milestone Pharmaceuticals Inc. | February 14, 2023 | 698,861 | 2.0% |
| SpringWorks Therapeutics, Inc. | September 19, 2022 | 3,421,541 | 5.7% |
| iTeos Therapeutics, Inc. | May 11, 2022 | 2,154,058 | 6.1% |
| Atreca, Inc. | February 14, 2022 | 2,202,333 | 7.2% |
| Biomea Fusion, Inc. | February 14, 2022 | 1,188,405 | 4.1% |
| Cabaletta Bio, Inc. | February 14, 2022 | 540,000 | 1.9% |
| CymaBay Therapeutics, Inc. | February 14, 2022 | ? | ? |
| DBV Technologies S.A. | February 14, 2022 | 1,067,299 | 1.9% |
| Elevation Oncology, Inc. | February 14, 2022 | 872,780 | 3.8% |
View Boxer Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-12 |
| 4 | 2024-02-08 |
| SC 13D/A | 2024-02-08 |
| 4 | 2024-01-25 |
| SC 13D/A | 2024-01-25 |
| SC 13G | 2024-01-18 |
| SC 13D/A | 2023-12-18 |
View Boxer Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.